The bispecific antibody is now the first HER2-targeted therapy for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

According to drugmaker Jazz Pharmaceuticals, the antibody binds to two extracellular sites on HER2, the first and only such ...

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Medically reviewed by Doru Paul, MDGallbladder cancer develops in the tissues of the gallbladder—a small, pear-shaped organ ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial access—one that ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...